Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors Academic Article uri icon

Overview

MeSH Major

  • Anilides
  • Hedgehog Proteins
  • Neoplasms
  • Pyridines
  • Signal Transduction

abstract

  • GDC-0449 has an acceptable safety profile and encouraging anti-tumor activity in advanced BCC and medulloblastoma. Further study in these and other cancer types is warranted.

publication date

  • April 15, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5244484

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-10-2745

PubMed ID

  • 21300762

Additional Document Info

start page

  • 2502

end page

  • 11

volume

  • 17

number

  • 8